CARLSBAD, Calif., Aug. 15, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2 million milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy (SMA).
The open-label extension study of ISIS-SMNRx is offered to those children with SMA who have completed dosing in Isis' previous studies. In this study, children with SMA are receiving a 12 ...
- $40 million in milestone payments from partners drives improved quarterly financial performance
- Conference Call Webcast Monday, August 4, 10:30 a.m. ET at www.isispharm.com
CARLSBAD, Calif., Aug. 4, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported pro forma net operating income of $1.1 million and a pro forma net operating loss (NOL) of $21.5 million for the three and six months ended June 30, 2014, respectively, compared to an NOL of $5.3 million and $799,...
-- ENDEAR Trial To Enroll 110 SMA Infants at Sites Globally
-- Dosage of First Infant Will Trigger $18 Million Milestone Payment
CARLSBAD, Calif., Aug. 1, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the initiation of a pivotal Phase 3 study evaluating ISIS-SMNRx in infants with spinal muscular atrophy (SMA), the most common genetic cause of infant mortality. Isis plans to dose the first infant in this study within the next few weeks, at which ...
CARLSBAD, Calif., July 28, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:
Isis Pharmaceuticals' Second Quarter 2014 Financial Results and Highlights Conference Call
Monday, August 4 at 10:30 a.m. ET / 7:30 a.m. PT
Live on the Internet. Simply l...
If you are interested in Isis Pharmaceuticals’ investment details, please visit our Investor FAQ page.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Online Investor Kit
Quickly download files right from our Investor Relations Web site.